Healthcare Innovators Quarraisha and Salim Abdool Karim Awarded Lasker-Bloomberg Public Service Award
Quarraisha and Salim Abdool Karim, a married duo of South African-born researchers, were recently awarded the prestigious 2024 Lasker-Bloomberg Public Service Award for their groundbreaking work in HIV prevention and treatment. The couple’s journey began during the early days of the HIV/AIDS epidemic in the 1980s when they were conducting research at Columbia University in New York. Witnessing the devastating impact of the disease firsthand, they decided to shift their focus to combating HIV and AIDS.
Upon returning to South Africa, Quarraisha and Salim realized the importance of empowering women to protect themselves from HIV. Over the next 18 years, they conducted extensive research on prophylactic treatments and engaged in advocacy and education efforts to raise awareness about HIV/AIDS. Their perseverance paid off when they turned their attention to tenofovir, a drug initially developed for herpes but later approved for HIV treatment by the FDA in 2001.
Through years of study and experimentation, the couple discovered that tenofovir could also be used to prevent HIV infection. Their groundbreaking research, presented at an AIDS conference in 2010, demonstrated the drug’s ability to reduce the risk of infection in women. This discovery laid the foundation for the development of HIV pre-exposure prophylaxis (PReP), a crucial tool in slowing down the spread of HIV/AIDS worldwide.
The Lasker Awards, often referred to as “America’s Nobel Prize,” recognize significant advancements in medical science. For Quarraisha and Salim, receiving this prestigious award is both humbling and inspiring. They view it as a recognition of their combined efforts in science, policy contributions, and service to humanity. The couple’s work has not only advanced medical research but has also made a meaningful impact on public health.
In other healthcare news, Iranian immigrant Maky Zanganeh has become a billionaire as the stock of Summit Therapeutics, the biotech firm she co-owns, soared in recent weeks. Despite being a relatively small player in the cancer medicine industry, Summit Therapeutics’ market capitalization surged, propelling Maky Zanganeh to billionaire status.
Additionally, several notable developments have taken place in the healthcare industry, including the FDA approval of arimoclomol for treating Niemann-Pick disease type C, a $58 million series A funding round for Constructive Bio, and a research collaboration between Novartis and Generate:Biomedicines.
The healthcare sector continues to see significant advancements and innovations, driven by the dedication and ingenuity of researchers, scientists, and entrepreneurs. As the industry evolves, it is crucial to recognize and celebrate the individuals and organizations making a difference in improving global health outcomes.
